高精度阴极直流电刺激治疗急性缺血性卒中:一项随机临床试验
该随机假对照3+3剂量递增首次人体试验在单中心于2018年10月至2021年7月纳入10例发病24小时内、有皮层缺血及可挽救半暗带、不适合再灌注治疗的急性缺血性卒中患者,7例接受高精度阴极直流电刺激(HD C-tDCS),3例假刺激。研究剂量为1 mA持续20分钟和2 mA持续20分钟。主要终点为可行性(随机至刺激启动时间)、耐受性(完成全程刺激率)和安全性(24小时症状性颅内出血率)。结果显示刺激实施中位时间12.5分钟(IQR 9-15分钟,最后4例),无永久性刺激中止;活性组低灌注区中位缩小100%(IQR 46%-100%),假刺激组增加325%(IQR 112%-412%);早期刺激后定量相对脑血容量变化活性组中位64%(IQR 40%-110%),假刺激组-4%(IQR -7%-1%),呈剂量反应模式;半暗带挽救活性组中位66%(IQR 29%-80.5%),假刺激组0%(IQR 0%-0%)。作者认为结果支持推进更大规模试验。
要点
- 在发病24小时内、有皮层缺血及可挽救半暗带、不适合再灌注治疗的急性缺血性卒中患者中,HD C-tDCS可在急诊快速启动,最后4例从随机到刺激启动中位12.5分钟(IQR 9-15分钟)。
- 研究剂量为1 mA持续20分钟和2 mA持续20分钟,患者耐受良好,无永久性刺激中止。
- 活性组低灌注区中位缩小100%(IQR 46%-100%),假刺激组增加325%(IQR 112%-412%)。
- 早期刺激后定量相对脑血容量变化活性组中位64%(IQR 40%-110%),假刺激组-4%(IQR -7%-1%),呈剂量反应模式。
- 半暗带挽救活性组中位66%(IQR 29%-80.5%),假刺激组0%(IQR 0%-0%);作者认为结果支持推进更大规模试验。
适用人群与场景
- 发病24小时内的急性缺血性卒中患者,有影像学证据的皮层缺血及可挽救半暗带,且不适合再灌注治疗。
- 单中心急诊场景,患者随访90天。
诊断标准与关键阈值
- 纳入标准:急性缺血性卒中发病24小时内;影像学证据的皮层缺血伴可挽救半暗带;不适合再灌注治疗。
- 剂量递增设计为3+3,研究剂量为1 mA持续20分钟和2 mA持续20分钟。
处置流程与药物剂量
- 为每位患者选择高精度阴极直流电刺激(HD C-tDCS)电极 montage,以仅向缺血区域输送电流。
- 研究剂量为1 mA持续20分钟和2 mA持续20分钟,采用3+3剂量递增设计。
研究设计与关键结果
- 随机、假对照、3+3剂量递增首次人体试验,单中心,2018年10月至2021年7月,纳入10例急性缺血性卒中患者,7例活性治疗、3例假刺激;患者平均(SD)年龄75(10)岁,6例(60%)女性,NIHSS评分平均(SD)8(7)。
- 主要终点:可行性为随机至研究刺激启动时间,最后4例中位(IQR)12.5分钟(9-15分钟);耐受性为完成全程刺激率,患者耐受良好,无永久性刺激中止;安全性为24小时症状性颅内出血率。
- 低灌注区变化:活性组中位(IQR)缩小100%(46%-100%),假刺激组增加325%(112%-412%)。
- 早期刺激后定量相对脑血容量变化:活性组中位(IQR)64%(40%-110%),假刺激组-4%(-7%-1%),呈剂量反应模式。
- 半暗带挽救:活性组中位(IQR)66%(29%-80.5%),假刺激组0%(IQR 0%-0%)。
证据类型、等级与局限
- 证据类型:随机、假对照、3+3剂量递增首次人体临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,HD C-tDCS在急诊环境中可高效启动且耐受良好,并可见半暗带挽救的获益信号,这些结果支持将HD C-tDCS推进至更大规模试验。
指南或共识出处
- ClinicalTrials.gov Identifier: NCT03574038
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Cathodal transcranial direct current stimulation (C-tDCS) provides neuroprotection in preclinical models of acute ischemic stroke (AIS) by inhibiting peri-infarct excitotoxic effects and enhancing collateral perfusion due to its vasodilatory properties.
OBJECTIVE: To report the first-in-human pilot study using individualized high-definition (HD) C-tDCS as a treatment of AIS.
DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial was sham controlled with 3 + 3 dose escalation design, and was conducted at a single center from October 2018 to July 2021. Eligible participants were treated for AIS within 24 hours from onset, had imaging evidence of cortical ischemia with salvageable penumbra, and were ineligible for reperfusion therapies. HD C-tDCS electrode montage was selected for each patient to deliver the electric current to the ischemic region only. Patients were followed for 90 days.
MAIN OUTCOMES AND MEASURES: Primary outcomes were feasibility, assessed as time from randomization to study stimulation initiation; tolerability, assessed by rate of patients completing the full study stimulation period; and safety, assessed by rates of symptomatic intracranial hemorrhage at 24 hours. The efficacy imaging biomarkers of neuroprotection and collateral enhancement were explored.
RESULTS: A total of 10 patients with AIS were enrolled, 7 were randomized to active treatment and 3 to sham. Patient age was mean (SD) 75 (10) years old, 6 (60%) were female, and National Institutes of Health Stroke Scale score was mean (SD) 8 (7). Two doses of HD C-tDCS (1 milliamp [mA] for 20 minutes and 2 mA for 20 minutes) were studied. The speed of HD C-tDCS implementation was a median (IQR) 12.5 minutes (9-15 minutes) in the last 4 patients. Patients tolerated the HD C-tDCS with no permanent stimulation cessation. The hypoperfused region was reduced by a median (IQR) 100% (46% to 100%) in the active group vs increased by 325% (112% to 412%) in sham. Change in quantitative relative cerebral blood volume early poststimulation was a median (IQR) 64% (40% to 110%) in active vs -4% (-7% to 1%) sham patients and followed a dose-response pattern. Penumbral salvage in the active C-tDCS group was median (IQR) 66% (29% to 80.5%) vs 0% (IQR 0% to 0%) in sham.
CONCLUSION AND RELEVANCE: In this randomized, first-in-human clinical trial, HD C-tDCS was started efficiently and well tolerated in emergency settings, with signals of beneficial effect upon penumbral salvage. These results support advancing HD C-tDCS to larger trials.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03574038.
参考来源
- Bahr-Hosseini M, Nael K, Unal G, et al. High-definition Cathodal Direct Current Stimulation for Treatment of Acute Ischemic Stroke: A Randomized Clinical Trial. JAMA Netw Open. 2023. PMID: 37342040. doi:10.1001/jamanetworkopen.2023.19231
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。